(P = .9) and in multivariate analyses (P = .7). Conclusion: Normal saline solution seems to be as effective as heparinized solution for keeping patent implanted ports in adult cancer patients. Implications for Practice: Switching from heparinized solution to normal saline for catheter intermittent lock of ports seems a safe procedure. L ong-term central vascular access devices (CVADs), implanted ports or external tunneled catheters (HickmanBroviac or similar catheters), provide reliable access for administration of drugs, blood products, parenteral nutrition, or blood sampling in patients undergoing treatment of malignancy. However convenient these devices may be, their use may be associated with complications that healthcare providers must be aware of to ensure their best management.
The occurrence of unexpected complications, especially infections and mechanical obstructions, may represent serious and unpleasant adverse effects for the patient, which may eventually require the removal of the device. Flushing and locking CVADs with anticoagulant solutions in the intervals between infusions are often included in the maintenance policy to prevent occlusion, although controversy exists over the most appropriate and safe approach.
The use of heparin to flush and lock CVADs is a wellknown practice and has been considered a standard of treatment in the past 1Y3 ; however, many concerns on the duration of heparin lock placement, the concentration of the heparin on the saline solution, 4 possible adverse reactions, 5, 6 heparininduced thrombocytopenia, and other coagulopathies related to the chronic use of heparin have been extensively reported. 7, 8 Although there is no clinical evidence that heparinized saline solutions may cause significant coagulopathy in patients with normal blood clotting, evidence is available suggesting that chronic use of even low doses of heparin may contribute to hemorrhage 9 and thrombocytopenia especially in dialysis 10 and/or cancer patients, 11, 12 which may lead to serious or lifethreatening complications. Thus, the use of normal saline as an alternative to heparin solution has been reported. 13, 14 Literature data are mainly related to pediatric patients and to the use of peripherally inserted venous catheters 15Y17 or Hickman-Broviac central venous catheters, 18 whereas no data are available concerning the efficacy of saline solution to lock totally implantable ports. Infusion Nursing Society (INS) Standards of Practice 19 recommend the use of heparinized solution at concentrations ranging from 10 to 100 U/mL as a standard of practice for locking purposes in central venous catheters without specific position for implanted ports. Likewise, Registered Nurses Association of Ontario suggests the use of heparinized solution locks for these devices. 20 Many manufacturers of ports also recommend this position, but the efficacy of this practice is controversial. For instance, National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in National Health Service Hospitals in England 21 and British Committee for Standards in Haematology 22 no longer firmly support heparinized saline solution as the unique one to be used to chronically flush and lock CVADs and suggest normal saline as a possible alternative. Flushing and locking procedures for implanted ports continue to be controversial; thus, the necessity for clinical trials to evaluate different policies has been recently strongly recommended. 23 This study was conducted to compare efficacy of heparinized solution versus normal solution for locking purposes only in ports of adult cancer patients.
n Materials and Methods A retrospective observational cohort study was carried out at the National Cancer Institute, IST Genova, Italy, including 610 port devices implanted in cancer patients from January 2007 to August 2009. The study was approved by the institutional review board. The study reports the port outcome observed in 2 groups of patients where 2 different means of maintaining catheter's patency were used, that is, by using heparinized solution versus using normal saline solution for locking the device in the period between infusions. Switching from heparinized solutions to normal saline solutions for locking CVADs was an established institutional policy since August 2008 based on a systematic review of literature and possible clinical advantages. 21, 22 The retrospective review was started in November 2010, after the change of locking policy, and was terminated by March 2011.
Study Design and Patient's Characteristics
This study compares the outcome of implants in 2 consecutive groups of patients and takes advantage of the fact that the 2 policies for locking ports were consistently used in all patients within each of 2 different consecutive periods, the remainder of a port management being similar in the 2 periods.
All consecutive 610 implanted ports in adult cancer patients at the National Cancer Institute, IST Genova, during the study period were included in the study. All patients were outpatients receiving chemotherapy or parenteral nutrition at fixed intervals according to protocol schedules for different types of tumors. In group A (from January 1, 2007, to July 31, 2008 ; n = 297), totally implanted ports were locked monthly with heparinized solution (10 mL saline/500 U heparin). This group of patients was assumed as the historical control group. In group B (from August 1, 2008, to December 31, 2009 ; n = 313), ports were locked monthly with 10 mL of normal saline solution. Locking procedure was carried out by a pulsatile method with the use of a 10-mL or a bigger syringe and a noncoring Huber needle. A positive pressure was maintained while removing the syringe at the end of locking to prevent reflux of blood and to produce the expected effect on catheter's patency. 20Y22 Locking procedures were performed at intervals of 1 month or at the end of every access for chemotherapy or nutritional purposes, as for institutional policy.
All patients were implanted with a 6.5-Fr silicone openended catheter port (LP-venous Health Port, Baxter SA, Lessines, Belgium) with an internal volume of 0.61 mL.
Surgical procedures were performed by 4 equally trained consultant surgeons under local anesthesia with sedation on demand (midazolam, 0.02Y0.05 mg/kg) in outpatient operating room facility under fluoroscopy and standardized surgical technique.
All patients were followed for a minimum period of 12 months and data collection terminated as of December 31, 2010 . Clinical patients' data and data on the duration and reason for failure of the ports were extracted from clinical hospital records. The medical records of each patient were reviewed retrospectively to abstract the following information: baseline clinical patient data, date of implant and removal of the port, and cause of removal, which was classified in 4 groups: irreversible occlusion (the primary study endpoint), other complications, end of treatment, or patient's death.
The primary aim of the study was to determine the efficacy of normal saline compared with heparinized solution on prevention of irreversible port occlusion requiring device's removal. The secondary aim was to evaluate the role, as independent prognostic factors for port irreversible occlusion, of the following characteristics: age, pathology, stage disease, access site, body side of access, concomitant parenteral nutrition infusion, and correct catheter tip position.
Study Endpoint and Definitions
1. The primary study endpoint, irreversible occlusion, was defined by the failure of 3 different consecutive attempts to restore catheter patency. First attempt was the inability to infuse fluids through the port despite patient's postural change and the use of manual pressure over the piston of a 10-mL or bigger syringe filled with saline, according to manufacturer's recommendation. In case of failure of the first attempt, second and third attempts consisted of push and lock delivery through the implanted port of a 2-mL saline/ 50,000 UI urokinase solution, repeated after 4 hours in case of failure. Persistence of the occlusion led to the port removal. 2. A correct catheter tip position was defined as the location of the tip within the lower third of the superior vena cava, as assessed by chest x-ray film performed immediately after surgery.
Statistical Analysis
The probability of irreversible occlusion in the 2 groups of implanted ports was estimated and compared in the 2 groups using standard survival analysis techniques, where survival was defined as the time from implantation to irreversible occlusion. The Kaplan-Meier Product Limit estimator was used to evaluate the cumulative probability of port occlusion at various times and to draw survival curves, which were compared by means of the log rank test. In these analyses, the follow-up times of patients with port explant because of end of therapy or patient's death were censored at these times and not considered as events.
To adjust for imbalances, between the 2 groups, in the distribution of factors potentially associated with the risk of occlusion and to assess the independent role of each of these actors in predicting the risk of occlusion, a multivariate, proportional hazard Cox's model was fitted to the data. The dependent variable was port occlusion, whereas the following factors were initially included in the model as covariates: flushing and locking solution (group A vs group B), age (G60 vs Q60 years), pathology (breast cancer vs colon cancer vs other gastrointestinal tract cancer vs ovarian cancer vs other), stage of the disease (any T, N0 vs T1-2, N+ vs stage IV disease and metastatic M+ patients), access site (internal jugular vein vs subclavian vein), body side of access (left side vs right side), concomitant parenteral nutrition infusion (yes vs no), and correct catheter tip position (yes vs no). The final model was obtained by means of a step-down backward procedure, based on the likelihood ratio test (P G .05), and hazard ratios, with their 95% confidence interval, associated with each prognostic factor were obtained by exponentiating the coefficient estimated in the model. The graphical representation of log{-log[S(t)]} against log t, where S(t) is the cumulative survival in each stratum at time t and t is the follow-up time, was used to confirm the assumption of proportionality. All P values are 2 sided; P values G .05 were considered significant.
n Results
During a 36-month period, 610 consecutive adult cancer patients were implanted a port at the National Cancer Research Institute in Genoa. All these unselected patients were included in a retrospective study to compare effectiveness of 2 different locking catheter maintenance policies. Two hundred ninety-seven (group A), implanted between January 1, 2007, and July 31, 2008 , were locked with heparinized solution, and 313 (group B), implanted between August 1, 2008, and December 31, 2009, with normal saline. Table 1 lists patient baseline clinical characteristics. Among patients in group B (normal saline) there was a higher proportion of patients with age 60 years or older (P = .063), breast cancer (P G .001), and internal jugular vein access for port placement (P G .001).
Median follow-up (Table 2) was 413 days (range, 14Y1327) for patients in group A and 386 days (range, 34Y865) for those in group B. One hundred sixty-seven (27.4%) ports were removed in the follow-up period (Table 2 ). In almost half of these cases (80 patients), removal was an elective procedure following the end of cancer treatment or patient's death. Removal for complications occurred in 87 of 610 (14.2%) patients.
Catheter irreversible occlusion was observed in 38 cases (6.2%) with a similar incidence in the heparinized solution group (n = 20) compared with the normal saline one (n = 18). no statistically significant difference was seen between the 2 groups (P = .907). Other complications requiring port removal, that is, catheter-related infection, local infection, catheter rupture, or skin erosion over the pocket of the port reservoir, occurred in 22 (7.4%) patients of group A (heparin solution lock) and in 27 (8.6%) patients of group B (normal saline solution lock; P = .58).
The lack of a significant association between the use of saline and an increased risk of failure for irreversible occlusion was confirmed in the multivariate analysis ( . In this analysis, patient age below 60 years or equal to or above 60 years, the type of cancer, the accessed vein during port positioning, and the body side were not independent risk factors for occlusion. An increased risk of implanted port occlusion of trending to significance was seen in patients with stage IV disease (HR, 1.9; 95% CI, 0.6Y5.8; P = .07), whereas the association between chemotherapy and parenteral nutrition (HR, 2.6; 95% CI, 1.1Y6.3; P = .03) and a catheter tip out of the lower third of the superior vena shown immediately after surgery (HR, 21.8; 95% CI, 10.8Y43.8; P G .001) were independent factors significantly associated with irreversible occlusion. When removals due to any type of complication were considered (Table 4) , the use of saline was again not significantly associated with port failure (HR 1.3; 95% CI, 0.6Y2.2; P = .3). The association between chemotherapy and parenteral nutrition (HR, 4.5; 95% CI, 2.8Y7.7; P G .001) and a catheter tip out of the lower third of the superior vena shown immediately after surgery (HR, 11.5; 95% CI, 6.8Y19.3; P G .001) were confirmed as significantly associated factors for occlusion.
n Discussion
Occlusion remains a serious complication of CVADs in patients with malignancy. Prophylactic strategies to reduce the frequency of this complication are mainly based on the use of standardized protocols for flushing and locking CVADs with heparinized saline solution, whereas the benefit of oral low dose warfarin or subcutaneous low weight molecular heparin remains unclear. 24 The issue of heparinization of vascular catheters, considered a useful practice since many years, continues to be controversial. Heparin by itself is not a thrombolytic agent; it does not directly cause clot lysis but prevents the progression of the existing clot by inhibiting any further clotting process, allowing naturally occurring clot lysis. Moreover, heparin has a very short half-life, from 60 to 90 minutes, and no data are available about its validity once diluted and inside the components of a vascular device (ie, catheter, port chamber, hubs).
Although the similar efficacy of normal saline solution as compared with heparin solution for maintaining patency of several intravascular catheters has been extensively reported in literature since many years, 14, 15 especially in children and peripherally indwelling vascular accesses, 4,16Y18 considerable uncertainty persists about the optimum choice of flushing and locking protocols of central venous catheters and implanted ports.
Two meta-analyses 13, 25 on efficacy, quality, and cost implications of heparin or saline flushing and intermittent locking procedures provided a scientific basis to designate saline as an alternative solution for maintaining intravenous patency of intravenous catheters in children. In a recent randomized clinical trial, Cesaro et al 18 failed to demonstrate statistically significant differences on catheter's patency between the 2 modalities of locking Broviac-Hickman external tunneled long-term catheters; central venous catheter survival rates were comparable with the 2 policies of locking catheters whereas the reported slightly higher incidence of mechanical complications shown in the normal saline group was related to differences on locking timing schedule between the 2 groups.
According to these observations, the guidelines of the British Department of Health 21 and the British Committee for Standards in Haematology 22 support the use of normal saline solution as an alternative to heparin solutions in central venous access devices of both pediatric patients and adults. Possible benefits to be obtained with this change of policy include the elimination of risks associated with extensive use of even low doses of heparin, the potential decrease of infection risks by lessening manipulation procedures, an amelioration of nursing resources for patient care because of decreased nursing time, and substantial savings. 9 In addition, the use of normal saline instead of heparinized solution may also represent an advantage for Muslims. Although Muslims are allowed to receive a drug of porcine origin when there is no alternative in a life-threatening situation, the use of heparin of porcine origin to prevent port occlusion may be a point of stress for many of them. 26 Despite the potential benefits of normal saline, switching to normal saline solution has not been widely suggested in literature for adult cancer patients bearing long-term totally implantable ports. A possible explanation for this fact may be ascribed to the fact that ports remain implanted for longer periods of time, even after the end of chemotherapy, and policies for locking procedures include 2 or more week intervals, thus reinforcing the medical belief about the effectiveness of heparin in maintaining catheter's patency. In contrast, our institutional policy for implanted port maintenance is based on monthly lock irrigations and/or immediately after drugs infusion. This study was a retrospective observational review of a large series including 610 unselected adult patients who were implanted with a port for cancer care. Representativeness of this unselected patient population allows conclusions to be applied to routine clinical practice.
The high proportion of stage IV patients (41%) is in accordance with the major use of implanted ports in advanced cancer patients. The prevalence of jugular vein in group B patients may be ascribed to our institutional standard of practice that since 2008 dictates this type of access, based on the lower incidence of postoperative complications as compared to subclavian vein access. The subclavian vein access versus jugular vein access has a relevant impact on early postoperative outcomes (ie, arterial puncture, pneumothorax, malposition), but there is uncertainty in literature about differences on late outcome and especially catheter occlusion. 27, 28 According to these reports, we believe that the choice of subclavian versus internal jugular vein access has a relative low impact regarding the incidence of central venous catheter occlusive events.
The 2 different types of locking solutions in this study, heparinized versus normal saline, did not affect efficacy of implanted ports. The difference in survival free from failure in group A (heparinized solution) and group B (saline solution) was statistically not significant (P = .907). Catheter irreversible occlusion occurred in 41 of 610 (6.7%) patients, with an incidence similar to that reported in literature. 24 The incidence was 7.4% and 6.1% in group A and group B of patients, respectively.
Multivariate analysis for risk factor confirmed the comparable efficacy of normal saline solution as an alternative to heparin solution for the maintenance of port patency with a marginal and statistically nonsignificant higher risk of occlusion (HR 1.2; 95% CI, 0.6-2.5; P = .7). Moreover, the use of saline solution was shown to be safe; the incidence of other complications (ie, catheter-related infection, local infection, catheter rupture, or skin erosion over the pocket of the port reservoir) was statistically not significant (P = .58) when compared with the historical heparinized solution control group.
The only independent factors significantly associated with catheter occlusions were inadequate catheter tip position, the use of implanted ports to infuse parenteral nutrition in association to chemotherapy, and the presence of stage IV or metastatic disease. We observed a nearly 22-fold increased risk for occlusion in patients who had a catheter tip in upper third of superior vena cava and more than 4-fold increased risk in patients who used the catheter for parenteral nutrition in association with chemotherapy.
These incidences were somehow higher than those reported in other studies. 29, 30 The use of implanted ports for both chemotherapy and total parenteral nutrition (TPN) is known to increase by itself infection risk and occlusive events; this was also shown in the 11% of the study population, in which ports were used both for chemotherapy and TPN. It is worthy of note that this increased hazard was independent from the use of heparinized solution or normal saline for catheter locking procedure. Nevertheless, most cancer patients initially receive an implanted port only for chemotherapy purposes, whereas the necessity of TPN comes later in their lives because of disease progression and worsening of the nutritional status. Implanting a second infusion device to be used solely for TPN might increase risk of infection or catheter occlusion to levels that are similar to or higher than those reported in this study.
Association between catheter occlusion, deep venous thrombosis, and metastatic disease has been previously reported 28, 31 ; the nearly 2-fold risk observed in our study is in accordance with the figures of these reports.
A further benefit of using normal saline might be represented by the availability of prefilled saline syringes that are becoming a popular tool for sterile injectable substances and drugs because of its ease of use, enhancement in compliance, lessening manipulation, and maintaining a continuous dynamic positive pressure during locking procedure, thus preventing catheter damage or rupture due to an excessive high injection pressure. Further studies on the use of prefilled saline syringes are advisable to evaluate the efficacy of their use for port locking purposes.
Nonetheless, some limitations of this study should be mentioned. First, this was not a randomized controlled study; as a consequence, the possibility of a false negative result cannot
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Cancer Nursing TM , Vol. 35, No. 4, 2012 n E41 be ruled out. However, the inclusion in the 2 groups of all consecutive patients implanted with a port device during the 2 study periods minimizes the risk of selection bias, whereas the uniformity of all port management procedures throughout the whole study period supports the absence of confounding due to other changes in practice. Second, the concentration of heparin (500 U/10 mL saline) used for locking solution in group A of patients was relatively weak. Although in peculiar situations, such as nephrology and hemodialysis patients, the use of heparin solution at concentrations of 100 U/mL or higher have been reported, most guidelines support concentrations ranging from 10 to 100 U/mL heparin. There is no available evidence in literature that indicates a close relationship between heparin concentration for locking solution and rate of catheter's occlusions. Our institutional policy for heparin concentration in locking solution used before July 2008 resulted from an attempt to balance expected efficacy with patient's safety. The reported incidence of occlusive events in our study, especially for those patients who receive heparinized solution for locking purposes (group A), was similar to that reported in literature. 29, 30 In conclusion, our study does not provide support to the hypothesis that heparinized saline is more effective than normal saline for locking procedures of implanted ports in cancer patients. Malposition of the catheter tip, the infusion of TPN in association to chemotherapy, and possibly advanced cancer disease are major risk factors for occlusive events to be taken into account. The use of intermittent normal saline solution lock seems to be a safe policy to guarantee catheter' patency in implanted ports.
